No Data
Cosmos Health 2024 Rev $54.4M
Press Release: Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
Cosmos Health | 10-K: FY2024 Annual Report
COSMOS HOLDINGS Earnings Preview: Recent $COSM Insider Trading, Hedge Fund Activity, and More
Cosmos Health Secures 5-Yr Contract Manufacturing Agreement With Pharmex for 1.5M Units of Antiseptic Drug AMBITASOL 1L
Express News | Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement With Pharmex for 1.5 Million Bottles of the Antiseptic Drug Ambitasol 1L
Love JL : There are plenty of good news, so why isn’t it rising.